Understanding exosomes in diabetic wound healing
- 1Department of Research Advanced PRF Education Jupiter Florida USA
- 2Department of Oral Implantology University of Wuhan Wuhan China
- 3Department of Periodontology University of Bern Bern Switzerland
Abstract
BACKGROUND: Diabetic wounds signify a major complication of diabetes mellitus, characterized by chronic inflammation, compromised angiogenesis, and high risk of infection, amputation, and mortality. Contemporary therapies remain limited in efficacy and durability. This review aimed to comprehensively assess exosome-mediated interventions as a cell-free regenerative approach for diabetic wound healing. METHODS: This narrative-scoping review was conducted using PubMed, Scopus, Web of Science, EMBASE, and Cochrane databases, identifying 176 preclinical and clinical studies. Included studies evaluated exosome origins, mechanisms of action, delivery platforms, and treatment outcomes in diabetic wound healing. RESULTS: Exosomes derived from mesenchymal stem cells, progenitor cells, blood products, immune cells, and natural sources consistently improved wound healing by enhancing angiogenesis, re-epithelialization, fibroblast proliferation, and extracellular matrix remodeling, while decreasing oxidative stress and chronic inflammation. Mechanistically, these effects were regulated via the stimulation of the PI3K/AKT, ERK/MAPK, STAT3, HIF-1α/VEGF, and Nrf2 signaling, together with the suppression of the AGE/RAGE-regulated ferroptosis and apoptosis. Biomaterial-based delivery systems, including scaffolds, microneedle patches, and hydrogels, significantly enhanced exosome retention, stability, and treatment efficacy. Across studies, exosome treatments showed expedited wound closure, enhanced collagen deposition, and improved vascularization in diabetic models. CONCLUSION: Exosome-mediated therapies represent a promising and multifaceted regenerative strategy for diabetic wound healing, addressing pivotal pathophysiological deficits. Nevertheless, challenges associated with standardization, scalability, and clinical validation must be resolved before widespread clinical application.
Related
- GelMA‐Based Hydrogel Encapsulating Astragalus Polysaccharides and Umbilical Cord Mesenchymal Stem Cell Exosomes Promotes Full‐Thickness Skin Wound Healing
- Abnormally low expression of tumor necrosis factor stimulated gene 6 (TSG-6) in obese type 2 diabetic mice contributes to altered inflammation and delayed cutaneous wound healing
- Allogeneic Human Bone Marrow‐Derived Mesenchymal Stem Cells Accelerate Diabetic Wound Healing via Inflammation Suppression and Angiogenesis Promotion: A Preclinical Study
- Advanced cell-laden hydrogels for diabetic wound healing: Biomaterial design, therapeutic mechanisms, and translational challenges
- Genome-directed discovery of an octalin-containing polyether ionophore improves diabetic skin wound healing.
BibTeX
@article{ahmad2026understanding,
title = {{Understanding exosomes in diabetic wound healing}},
author = {Paras Ahmad and Yulan Wang and Y J Zhang and Anton Sculean and Richard J. Miron},
journal = {Periodontology 2000},
year = {2026},
month = may,
doi = {10.1111/prd.70055},
url = {https://doi.org/10.1111/prd.70055},
note = {CC BY},
}
RIS
TY - JOUR
TI - Understanding exosomes in diabetic wound healing
AU - Paras Ahmad
AU - Yulan Wang
AU - Y J Zhang
AU - Anton Sculean
AU - Richard J. Miron
PY - 2026
DA - 2026/05/24
JO - Periodontology 2000
DO - 10.1111/prd.70055
UR - https://doi.org/10.1111/prd.70055
AB - BACKGROUND: Diabetic wounds signify a major complication of diabetes mellitus, characterized by chronic inflammation, compromised angiogenesis, and high risk of infection, amputation, and mortality. Contemporary therapies remain limited in efficacy and durability. This review aimed to comprehensively assess exosome-mediated interventions as a cell-free regenerative approach for diabetic wound healing. METHODS: This narrative-scoping review was conducted using PubMed, Scopus, Web of Science, EMBASE, and Cochrane databases, identifying 176 preclinical and clinical studies. Included studies evaluated exosome origins, mechanisms of action, delivery platforms, and treatment outcomes in diabetic wound healing. RESULTS: Exosomes derived from mesenchymal stem cells, progenitor cells, blood products, immune cells, and natural sources consistently improved wound healing by enhancing angiogenesis, re-epithelialization, fibroblast proliferation, and extracellular matrix remodeling, while decreasing oxidative stress and chronic inflammation. Mechanistically, these effects were regulated via the stimulation of the PI3K/AKT, ERK/MAPK, STAT3, HIF-1α/VEGF, and Nrf2 signaling, together with the suppression of the AGE/RAGE-regulated ferroptosis and apoptosis. Biomaterial-based delivery systems, including scaffolds, microneedle patches, and hydrogels, significantly enhanced exosome retention, stability, and treatment efficacy. Across studies, exosome treatments showed expedited wound closure, enhanced collagen deposition, and improved vascularization in diabetic models. CONCLUSION: Exosome-mediated therapies represent a promising and multifaceted regenerative strategy for diabetic wound healing, addressing pivotal pathophysiological deficits. Nevertheless, challenges associated with standardization, scalability, and clinical validation must be resolved before widespread clinical application.
SN - 0906-6713
SN - 1600-0757
ER -